FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment

FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment

Accelerated approval (AA) by the FDA enables earlier access to promising new therapies. Health Canada has a similar process. Canada implemented a national health technology assessment (HTA) for reimbursement decisions in 2011. This study evaluated regulatory and funding timelines and decisions for F...

Full description

Bibliographic Details
Main Authors:	Cheryl Ho, Howard J. Lim, Dean A. Regier
Format:	Article
Language:	English
Published:	MDPI AG 2022-01-01
Series:	Current Oncology
Subjects:	accelerated approval FDA Health Canada health technology assessment CADTH
Online Access:	https://www.mdpi.com/1718-7729/29/2/36

Similar Items

Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway
by: Mahnum Shahzad, et al.
Published: (2024-12-01)

An empirical analysis of overall survival in drug approvals by the US FDA (2006–2023)
by: Josh Elbaz, et al.
Published: (2024-04-01)

Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality
by: Rekha Tamatam, et al.
Published: (2023-02-01)

FDA Approvals of Biologics in 2022
by: Alexander C. Martins, et al.
Published: (2023-05-01)

Impact of Oncology Drug Review Times on Public Funding Recommendations
by: Marya Hussain, et al.
Published: (2023-08-01)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
by: Catherine Lau, et al.
Published: (2022-10-01)

Drugs, Devices, and the FDA: Part 1
by: Gail A. Van Norman, MD
Published: (2016-04-01)

The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov
by: Norring SA, et al.
Published: (2024-04-01)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
by: Juliana T. W. Tong, et al.
Published: (2021-09-01)

Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
by: Catherine Y. Lau, et al.
Published: (2024-09-01)

Artificial Intelligence in Perioperative Medicine: A Proposed Common Language With Applications to FDA-Approved Devices
by: Ryan L. Melvin, et al.
Published: (2022-04-01)

Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
by: Daniel A. Rodrigues, et al.
Published: (2019-05-01)

Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
by: Alexander C. Martins, et al.
Published: (2022-09-01)

Comparison of approval procedures for medical devices in Europe and the USA
by: Vila Wagner Marcel, et al.
Published: (2019-09-01)

The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health
by: Chakrapani Balijepalli, et al.
Published: (2024-04-01)

Fully automated virtual screening pipeline of FDA-approved drugs using Caver Web
by: Milos Musil, et al.
Published: (2022-01-01)

Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice
by: Chunfeng Li, et al.
Published: (2017-10-01)

In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
by: Ridwan Abiodun Salaam, et al.
Published: (2025-03-01)

2023 FDA TIDES (Peptides and Oligonucleotides) Harvest
by: Danah Al Shaer, et al.
Published: (2024-02-01)

A Computational Study of Efficient Combinations of FDA-Approved Drugs and Dietary Supplements in Endometrial Cancer
by: Madhurima Mondal, et al.
Published: (2024-01-01)

High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses
by: Cuiling Ding, et al.
Published: (2022-06-01)

Regulating vaccines at the FDA: development and licensure of Zika vaccines
by: Marion F. Gruber, et al.
Published: (2017-06-01)

FDA approves leniolisib (Joenja) as the first treatment for APDS: A breaththrough in the field of immunology
by: Muhammad Talha, et al.
Published: (2024-01-01)

A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
by: Kaifeng Liu, et al.
Published: (2024-03-01)

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
by: Annie Mayence, et al.
Published: (2019-03-01)

Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia
by: Graeme Ball, et al.
Published: (2022-10-01)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
by: Dr. Chenshu Xu, et al.
Published: (2021-09-01)

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
by: Ye Wang, et al.
Published: (2021-06-01)

Design and synthesis of fluorine aromatic scaffolds containing drugs approved by the US FDA from 2002 to 2022
by: Pengfei Xu, et al.
Published: (2024-01-01)

FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
by: Aleksandra Sochacka-Ćwikła, et al.
Published: (2022-03-01)

Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
by: Amelia D. Dahlén, et al.
Published: (2022-01-01)

A review of new drugs approved by the food and drug administration in 2022
by: Arjun Swaminathan, et al.
Published: (2023-10-01)

CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value’s Worth
by: Pierre J. A. Villeneuve, et al.
Published: (2023-04-01)

Screening of an FDA-Approved Library for Novel Drugs against <i>Y. pestis</i>
by: David Gur, et al.
Published: (2021-01-01)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
by: Sam Salek, et al.
Published: (2019-03-01)

Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library
by: Jie Feng, et al.
Published: (2014-01-01)

Review of approvals and recalls of US specific medical devices in general and plastic surgery
by: Aashka Shah, et al.
Published: (2023-03-01)

Currently Available Non-Balloon Devices
by: Hang Lak Lee
Published: (2018-09-01)

Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases <i>Pseudomonas aeruginosa</i> Tolerance to Ciprofloxacin
by: Yael Schlichter Kadosh, et al.
Published: (2024-11-01)

A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2
by: Madhura Punekar, et al.
Published: (2022-09-01)